Denali Advisors’s Vor Biopharma VOR Stock Holding History

Denali Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-325	Closed	-$20.1K	–	543
2023 Q2	$20.1K	Hold	325	–	–	0.01%	341
2023 Q1	$35K	Buy	+325	New	+$36K	0.01%	252

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Denali Advisors's VOR Position: Q3 2023 in Review

Denali Advisors sold out of Vor Biopharma (VOR) in Q3 2023, closing a stake of 325 shares — an estimated $20.1K sold.

Denali Advisors first reported a position in VOR in Q1 2023 and held it in 2 quarters. The position peaked at $35K in Q1 2023. 59 funds tracked by Wall St. Rank hold VOR as of Q3 2023.

Denali Advisors reported no remaining Vor Biopharma position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 325 Vor Biopharma shares in Q3 2023, an estimated $20.1K.
Denali Advisors first reported a position in Vor Biopharma in Q1 2023 and held it in 2 quarters.
Denali Advisors's Vor Biopharma position peaked at $35K in Q1 2023.
59 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.